Search Result

Results for "

prostate cancer

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PSMA (66) 11β-HSD (1) 17β-HSD (8) 3β-HSD (4) 5 alpha Reductase (3) 5-HT Receptor (2) Ack1 (1) Acyltransferase (2) ADC Antibody (8) ADC Linker (3) ADC Payload (3) Adenosine Deaminase (1) Adenosine Receptor (1) Adenylate Cyclase (2) Adrenergic Receptor (12) Akt (53) Aldehyde Dehydrogenase (ALDH) (4) Aldose Reductase (13) Amino Acid Derivatives (2) Amino acid Transporter (1) Aminoacyl-tRNA Synthetase (1) Aminopeptidase (5) AMPK (7) Androgen Receptor (184) Angiotensin-converting Enzyme (ACE) (2) Annexin A (1) Antibiotic (19) Antibody-Drug Conjugates (ADCs) (7) AP-1 (2) Apelin Receptor (APJ) (1) Apoptosis (289) Arenavirus (1) Arrestin (1) ASCT (1) Atg4 (1) Atg8/LC3 (1) ATM/ATR (3) ATP Synthase (3) Aurora Kinase (4) Autophagy (32) AUTOTACs (1) Bacterial (38) Bcl-2 Family (29) Biochemical Assay Reagents (17) BMX Kinase (2) Bombesin Receptor (4) Bradykinin Receptor (1) c-Fms (1) c-Kit (1) c-Met/HGFR (1) c-Myc (16) Cadherin (2) Calcium Channel (7) Cannabinoid Receptor (3) Carbonic Anhydrase (2) Carboxylesterase (CES) (1) Carboxypeptidase (4) Carnitine Palmitoyltransferase (CPT) (3) Casein Kinase (1) Caspase (60) Cathepsin (4) CCR (3) CD276/B7-H3 (2) CD3 (5) CD73 (2) CDK (30) Ceramidase (1) CGRP Receptor (3) Checkpoint Kinase (Chk) (3) Chloride Channel (2) Cholecystokinin Receptor (1) Complement System (1) COX (6) CTLA-4 (1) CXCR (5) Cyclic GMP-AMP Synthase (1) Cyclophilin (1) Cytochrome P450 (22) Dengue Virus (1) Deubiquitinase (2) Dihydroorotate Dehydrogenase (1) DNA Alkylator/Crosslinker (2) DNA-PK (2) DNA/RNA Synthesis (29) Dopamine Receptor (1) Drug Derivative (16) Drug Intermediate (5) Drug Isomer (1) Drug Metabolite (18) Drug-Linker Conjugates for ADC (2) DYRK (4) E1/E2/E3 Enzyme (7) E3 Ligase Ligand-Linker Conjugates (2) EGFR (14) Endogenous Metabolite (31) Endonuclease (1) Endothelin Receptor (3) Enteropeptidase (2) Environmental Pollutants (12) Ephrin Receptor (2) Epigenetic Reader Domain (45) ERK (13) Estrogen Receptor/ERR (20) Eukaryotic Initiation Factor (eIF) (1) Exosomes (1) FAAH (1) FAK (3) FAP (1) Farnesyl Transferase (4) Fatty Acid Synthase (FASN) (11) Fc Receptor (FcR) (1) Ferroptosis (5) FGFR (1) FKBP (1) Fluorescent Dye (6) Folate Receptor (FR) (1) FOXO (3) Fungal (13) FXR (4) GABA Receptor (3) Galectin (1) Gap Junction Protein (2) Gli (1) Glucocorticoid Receptor (1) GLUT (2) Glutathione Peroxidase (2) Glutathione S-transferase (1) Glycosidase (4) GnRH Receptor (28) GSK-3 (5) HBV (3) HDAC (15) Hedgehog (2) Heme Oxygenase (HO) (3) HIF/HIF Prolyl-Hydroxylase (5) Histamine Receptor (1) Histone Acetyltransferase (21) Histone Demethylase (21) Histone Methyltransferase (25) HIV (12) HIV Protease (1) HPV (2) HSP (16) HSV (2) IAP (4) ICMT (1) IGF-1R (2) iGluR (1) IKK (1) Indoleamine 2,3-Dioxygenase (IDO) (2) Influenza Virus (2) Insecticide (3) Insulin Receptor (3) Integrin (5) Interleukin Related (18) IRE1 (2) Isotope-Labeled Compounds (34) JAK (7) JNK (5) Kallikrein (1) Keap1-Nrf2 (6) Kinesin (1) Kisspeptin Receptor (4) Leukotriene Receptor (2) Ligands for E3 Ligase (5) Ligands for Target Protein for PROTAC (12) Liposome (4) Lipoxygenase (6) LYTACs (2) MAPKAPK2 (MK2) (1) MDM-2/p53 (10) MEK (1) MetAP (2) Methionine Adenosyltransferase (MAT) (1) METTL3 (2) mGluR (1) MicroRNA (1) Microtubule/Tubulin (23) Mitochondrial Metabolism (5) Mitophagy (2) Mitosis (4) MMP (22) MNK (5) Molecular Glues (12) Monoamine Oxidase (6) mTOR (17) Mucin (1) NADPH Oxidase (2) NAMPT (1) Necroptosis (3) Nectin-4 (1) NEKs (1) Neurokinin Receptor (1) NF-κB (32) NO Synthase (2) NOD-like Receptor (NLR) (2) Notch (2) Nuclear Factor of activated T Cells (NFAT) (1) Nucleoside Antimetabolite/Analog (1) Opioid Receptor (4) Organoid (2) Orphan Nuclear Receptor (2) Orthopoxvirus (1) Oxidative Phosphorylation (1) P-glycoprotein (3) p38 MAPK (12) PAK (1) Paraptosis (1) Parasite (19) PARP (33) PD-1/PD-L1 (5) PDGFR (1) PDK-1 (2) Peptide-Drug Conjugates (PDCs) (4) PERK (1) PGE synthase (2) Phosphatase (10) Phosphodiesterase (PDE) (3) Phosphoglycerate Dehydrogenase (PHGDH) (1) Phospholipase (4) Phytohormone (1) PI3K (31) PIKfyve (1) Pim (11) PIN1 (1) PKC (6) Platelet-activating Factor Receptor (PAFR) (1) Polo-like Kinase (PLK) (5) Potassium Channel (3) PPAR (9) Progesterone Receptor (6) Prostaglandin Receptor (7) PROTAC Linkers (2) PROTAC-Linker Conjugates for PAC (1) PROTACs (64) Protease Activated Receptor (PAR) (1) Proteasome (3) PTEN (1) PTHR (1) Pyroptosis (4) Pyruvate Carboxylase (PC) (1) Pyruvate Kinase (1) RAD51 (1) Radionuclide-Drug Conjugates (RDCs) (17) Raf (3) RANKL/RANK (1) RAR/RXR (3) Ras (6) Reactive Oxygen Species (ROS) (45) Reference Standards (88) Reverse Transcriptase (8) Ribosomal S6 Kinase (RSK) (1) RIO Kinase (1) ROCK (2) ROR (5) ROS Kinase (2) RSV (1) SARS-CoV (10) SDCBP (1) Sec61 (1) Ser/Thr Protease (5) SF3B1 (2) SGK (1) SHP1 (2) SHP2 (3) Sigma Receptor (3) Sirtuin (4) SOD (3) Somatostatin Receptor (2) SOS1 (3) Src (3) STAT (17) Survivin (6) SWI/SNF Complex (1) TAM Receptor (1) Telomerase (7) TGF-beta/Smad (2) TGF-β Receptor (1) Tim3 (1) TLK (2) TMV (1) TNF Receptor (7) Toll-like Receptor (TLR) (3) Topoisomerase (21) Transmembrane Glycoprotein (5) Trk Receptor (1) TRP Channel (6) Tyrosinase (2) UGT (1) VD/VDR (2) VEGFR (20) Virus Protease (2) VSV (1) WDR5 (1) Wee1 (2) Wnt (9) YAP (2) YB-1 (1) YTHDF (1) Zinc Finger Protein (1) β-catenin (8)
By Research Areas:	Cancer (1116) Cardiovascular Disease (40) Endocrinology (62) Infection (82) Inflammation/Immunology (123) Metabolic Disease (54) Neurological Disease (57)
Click Chemistry:	PROTAC Synthesis (2) Alkynes (6)
Oligonucleotides:	Solvents (1) Pegylated Lipids (2) Nucleotide Analogs (2) Aptamers (3) Antisense Oligonucleotides (3) Adenine Nucleotide (2) Cholesterol (3)

1154

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

142

Natural
Products

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

GMP Molecules

Bicalutamide 15+ Cited Publications	Androgen Receptor Autophagy	Cancer
Bicalutamide is an orally active non-steroidal androgen receptor (AR) antagonist. Bicalutamide can be used for the research of prostate cancer .

Rosopatamab HUJ-591; TLX591	PSMA Radionuclide-Drug Conjugates (RDCs)	Cancer
Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 ( ¹⁷⁷Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency .

AU-24118 1 Publications Verification	PROTACs Epigenetic Reader Domain	Cancer
AU-24118 is a selective and orally bioavailable PROTAC degrader of mSWI-SNF ATPases (SMARCA2 and SMARCA4) and PBRM1. AU-24118 integrates a bait moiety binding to the bromodomains of SMARCA2 and SMARCA4, along with a ligand moiety for CRBN ligase. AU-24118 demonstrates tumor regression in prostate cancer model. AU-24118 can be studied to combat prostate cancer. (Pink: PBRM1/SMARCA2,4 ligand (HY-171774); Blue: CRBN ligand (HY-171775)) .

Zadavotide guraxetan 2 Publications Verification PSMA I&T; PNT-2002	PSMA	Cancer
PSMA I&T is an effective inhibitor of prostate-specific membrane antigen (PSMA). PSMA I&T can be used for SPECT/CT imaging and radionuclide studies in triple-negative breast cancer and prostate cancer (PCa) .

Anti-STEAP2 Antibody AZD0516 antibody	ADC Antibody	Cancer
Anti-STEAP2 Antibody (AZD0516 antibody) is an antibody targeting six-transmembrane epithelial antigen of the prostate 2 (STEAP2). Anti-STEAP2 Antibody can be used for the synthesis of the ADC molecule AZD0516 (HY-173639). Anti-STEAP2 Antibody can be used in the research of prostate cancer .

HUHS015	PSMA	Cancer
HUHS015 is a potent prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitor with an IC₅₀ of 0.67μM for PCA-1 .

AZD0516	Antibody-Drug Conjugates (ADCs) Topoisomerase Apoptosis	Cancer
AZD0516 is a first-in-class antibody-drug conjugate (ADC) targeting *six-transmembrane epithelial antigen of the prostate-2 (STEAP2). The anti-STEAP2 monoclonal antibody (mAb) is conjugated via interchain cysteines to a maleimide-reactive, β-glucuronidase-cleavable linker (HY-173635) bearing the topoisomerase 1 inhibitor, Exatecan (HY-13631). AZD0516 can be used for the study of prostate* cancer .

AZA1 1 Publications Verification Rac1/Cdc42-IN-1	Ras Apoptosis	Cancer
AZA1 is a potent dual inhibitor of Rac1 and Cdc42. AZA1 induces prostate cancer cells apoptosis and inhibits prostate cancer cells proliferation, migration and invasion .

Pelgifatamab BAY-2315497; PSMA-TTC	PSMA Apoptosis	Cancer
Peligifatamab is a PSMA-targeted α-radioimmunoconjugate with an EC₅₀ of 1.2 nM against human targets. Peligifatamab induces DNA damage, DNA double-strand breaks, cell cycle arrest and apoptosis (Apoptosis) in PSMA-positive prostate cancer cells. Peligifatamab reduces cell viability in a manner dependent on cellular PSMA expression levels. Peligifatamab inhibits tumor growth and tumor-induced abnormal bone growth in prostate cancer bone metastasis models. Peligifatamab exhibits antitumor efficacy in subcutaneous prostate cancer models and xenograft models. Peligifatamab can be used for the research of metastatic castration-resistant prostate cancer .

KDM4-IN-3	Histone Demethylase	Cancer
KDM4-IN-3 (Compound 15) is a KDM4 inhibitor (IC₅₀ = 871 nM) that exhibits improved potency in biochemical assays. KDM4-IN-3 is cell-permeable and kills prostate cancer cells at low micro molar concentrations. KDM4-IN-3 inhibits growth of prostate cancer cell lines and increases the H3K9me3 abundance. KDM4-IN-3 can be studied in research for prostate cancer .

EN1441	Androgen Receptor	Cancer
EN1441 is a covalent degrader targeting the androgen receptor (AR) with an EC₅₀ value of 4.2 μM and its truncated variant AR-V7. EN1441 selectively and potently degrades both AR and AR-V7 in androgen-independent prostate cancer cells. EN1441 is promising for research of androgen-independent prostate cancers .

p-SCN-Bn-TCMC	Biochemical Assay Reagents	Cancer
p-SCN-Bn-TCMC is a bifunctional chelator. Its cyclen backbone binds Hg ²⁺, while its isothiocyanate group allows for conjugation to biomolecules. p-SCN-Bn-TCMC can be used in the research of prostate cancer .

TRPM4-IN-2 5 Publications Verification NBA	TRP Channel	Cancer
TRPM4-IN-2 (NBA) is a potent transient receptor potential melastatin 4 (TRPM4) inhibitor with an IC₅₀ value of 0.16 μM. TRPM4-IN-2 can be used for researching prostate cancer and colorectal cancer .

Inixaciclib NUV-422	CDK	Neurological Disease Cancer
Inixaciclib (NUV-422) is a blood-brain barrier-penetrant inhibitor of CDK2, CDK4 and CDK6. Inixaciclib inhibits cancer cell growth. Inixaciclib induces anti-tumor activity in xenograft models of glioblastoma, CDK4/CDK6 inhibitor-resistant HR ⁺ HER2 ^- metastatic breast cancer, and anti-androgen-resistant prostate cancer. Inixaciclib can be used for the research of relapsed or metastatic castration-resistant prostate cancer .

Prunetrin Trifoside; Prunetin 4′-O-β-D-glucopyranoside	Others	Cancer
Prunetrin (Trifoside) is a flavonoid identified as a potential anti-prostate cancer agent in in silico screening .

NSC636819	Histone Demethylase	Cancer
NSC636819 is a competitive and selective inhibitor of KDM4A/KDM4B. KDM4A/KDM4B are potential progression factors for prostate cancer. NSC636819 has the potential for the research of cancer diseases, especially prostate cancer .

Torularhodin	Apoptosis	Cancer
Torularhodin is a carotenoid with anti-cancer activity. Torularhodin induces apopotsis of tumor cells and can be used for the study of prostate cancer .

PIK5-12d 1 Publications Verification	PROTACs PIKfyve Autophagy	Cancer
PIK5-12d is a PROTAC PIKfyve degrader (DC₅₀ = 1.48 nM). PIK5-12d induces massive cytoplasmic vacuolization and blocks autophagic flux in multiple prostate cancer cells. PIK5-12d inhibits prostate cancer cell proliferation. PIK5-12d significantly suppresses tumor proliferation in mice bearing LTL-331R human prostate cancer PDX tumors. PIK5-12d can be used for the study of prostate cancer. (Pink: PIKfyve ligand (HY-175631), Blue: VHL Ligand (HY-125845), Black: Linker, PIKfyve ligand-linker conjugate (HY-175632)) .

MnTE-2-PyP chloride BMX-010 chloride	Reactive Oxygen Species (ROS)	Cancer
MnTE-2-PyP (BMX-010) chloride is a ROS scavenger and potent radioprotector. MnTE-2-PyP also is a manganese porphyrin, protects normal prostate tissue from radiation damage. MnTE-2-PyP can be used for the research of diabetic prostate cancer .

Ar-V7-IN-1	Androgen Receptor	Cancer
Ar-V7-IN-1 is a potent inhibitor of Ar-V7. Ar-V7-IN-1 inhibits the transcriptional activity of androgen receptor (AR) and the secretion of prostate-specific antigen (PSA) with an eGFP IC₅₀ of 1232 nM and the PSA IC₅₀ of 1391 μM. Ar-V7-IN-1 has the potential for the research of various indications, in particular cancers such as prostate cancer .

ET516	Androgen Receptor	Cancer
ET516 is a potent inhibitor of Androgen Receptor. ET516 significantly inhibits the proliferation and tumor growth of prostate cancer cells expressing AR-resistant mutants .

PNT2001 LY4181530; PSMA-62	PSMA	Cancer
PNT2001 (LY4181530) is a potent prostate specific membrane antigen (PSMA) ligand with an IC₅₀ of 3.1 nM. PNT2001 can improve cellular internalization. 177Lu- and 225Ac-labeled PNT2001 can be used in prostate cancer research .

HYNIC-PSMA	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
HYNIC-PSMA is a ligand for molecular imaging of tumors. Hynic-psma consists of two components: HYNIC (6-hydrazinonicotinamide) and PSMA (Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules, such as ¹⁸⁸Re-HYNIC-PSMA. PSMA is a membrane antigen that is specifically expressed on the surface of prostate cancer cells. HYNIC-PSMA can be used in prostate cancer research . HYNIC-PSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

Antide D-21074; ORF 23541	GnRH Receptor	Cancer
Antide (D-21074) is a potent LHRH antagonist. Antide also can be used for the research of prostatic cancer .

Honokiol DCA 1 Publications Verification Honokiol dichloroacetate	Androgen Receptor	Cancer
Honokiol DCA (Honokiol dichloroacetate) is a dichloroacetate analog of Honokiol. Honokiol DCA can inhibit the growth of human prostate cancer cells in vitro and suppress the androgen receptor (AR) protein level .

cIAP1 ligand 1 E3 ligase Ligand 12	Ligands for E3 Ligase	Cancer
cIAP1 ligand 1 is the LCL161 derivative based IAP ligand. cIAP1 ligand 1 can be connected to the ABL ligand for protein by a linker to form SNIPER. cIAP1 ligand 1 can be used in prostate cancer research .

Astragenol	Others	Inflammation/Immunology Cancer
Astragenol is an intermediate used for Astragenol derivative synthesis. Astragenol derivatives are promising anti-inflammatory agents for prostate cancer research .

NOTA-P2-RM26	Bombesin Receptor	Cancer
NOTA-P2-RM26 is an antagonist of Bombesin (HY-P0195) analogs, and the gastrin-releasing peptide receptor (GRPR/BB2) is a molecular target for prostate cancer visualization. NOTA-P2-RM26 is labeled with ¹¹¹In and ⁶⁸Ga for prostate cancer imaging studies using PET and SPECT/CT .

RM-581	Apoptosis	Cancer
RM-581, aminosteroid, is an orally active anticancer agent. RM-581 shows anticancer potency against pancreatic, breast, prostate, and ovarian cancers. RM-581 induces endoplasmic reticulum stress and apoptosis via disturbance of cancer cell cholesterol homeostasis. RM-581 can be used for the research of cancer, such as prostate cancer and breast cancer .

Venuloside A ESK246	Others	Cancer
Venuloside A is a potent inhibitor of LAT3. Venuloside A inhibits the leucine uptake in LNCaP prostate cancer cells with an IC₅₀ of 8.12 μM .

D2A21 TFA	Bacterial	Infection Cancer
D2A21 TFA is an antimicrobial peptide with significant antimicrobial activity against Pseudomonas and bactericidal effect on burn scabs. D2A21 TFA has antitumor activity and can be used in prostate cancer research .

Goserelin ICI 118630	GnRH Receptor Apoptosis	Endocrinology Cancer
Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer .

FA2 glycan (G0F) FA2 N-linked oligosaccharide; F(6)A2 glycan	Biochemical Assay Reagents	Cancer
FA2 glycan (G0F) (FA2 N-linked oligosaccharide; F(6)A2 glycan) is a core-fucosylated biantennary N-linked oligosaccharide that serves as a prostate cancer biomarker. The level of FA2 glycan (G0F) is higher in prostate cancer than in benign prostatic hyperplasia, and it is further elevated in advanced prostate cancer with a Gleason score ≥8 compared with both benign prostatic hyperplasia and low-/intermediate-risk prostate cancer. FA2 glycan (G0F) can be used in prostate cancer research .

Tigapotide PCK-3145	Apoptosis PTHR	Metabolic Disease Cancer
Tigapotide (PCK-3145) is a synthetic 15-mer peptide derived from prostate-secretory protein, and acts as an antineoplastic agent. Tigapotide inhibits tumor growth, experimental bone metastasis, and malignancy-associated hypocalcemia. Tigapotide induces apoptosis in prostate cancer cells and tumors, and suppresses the growth of prostate cancer cells. Tigapotide inhibits the production of parathyroid hormone-related protein (PTHrP) in tumors and plasma. Tigapotide reduces plasma calcium levels in hypercalcemic tumor-bearing rats. Tigapotide is applicable for the research of prostate cancer and malignancy-associated hypercalcemia .

MIP-1072	PSMA	Cancer
MIP-1072 is a small molecule specific prostate-specific membrane antigen (PSMA) inhibitor. MIP-1072 inhibits the glutamate carboxypeptidase activity of PSMA with an K_i value of 4.6 nM. MIP-1072 is promising for research of prostate cancer .

GTX-758	Estrogen Receptor/ERR	Cancer
GTX-758 is an orally active, nonsteroidal, selective agonist of ERα. GTX-758 plays an important role in castration resistant prostate cancer (CRPC) research .

AR Degrader-1	Molecular Glues Androgen Receptor E1/E2/E3 Enzyme	Cancer
AR Degrader-1 (Compound ML 2-9) is a molecular glue androgen receptor (AR) monovalent degrader. AR Degrader-1 degrades AR through DCAF16 (E3 ligase) without obvious cytotoxicity in LNCaP prostate cancer cells .

Degarelix acetate 10+ Cited Publications FE 200486	GnRH Receptor	Cancer
Degarelix acetate (FE 200486) is a decapeptide that shows high affinity/selectivity to human gonadotropin-releasing hormone (GnRH) receptor (IC₅₀ = 3 nM). Degarelix acetate (FE 200486) is used for the research of prostate cancer .

Neochamaejasmine A	Apoptosis	Cancer
Neochamaejasmine A is a biflavonoid that can be isolated from the roots of Stellera chamaejasme L.. Neochamaejasmine A inhibits proliferation, induces cell cycle arrest and apoptosis in tumor cells. Neochamaejasmine A can be used in the research of cancers such as prostate cancer, hepatoma cancer .

Isobutyramide	Drug Metabolite	Cancer
Aldehyde Dehydrogenase Isobutyramide is an orally active liver alcohol dehydrogenase (LADH2) inhibitor. Isobutyramide inhibits ethanol metabolism and enhances differentiation-related gene expression, inducing cell cycle arrest and significantly reducing the growth rate of prostate cancer cells (LNCaP). Isobutyramide is promising for research of advanced prostate cancer .

EC-70124	IKK JAK STAT NF-κB	Cancer
EC-70124 is an orally active multikinase inhibitor targeting IKKβ and JAK2. EC-70124 blocks IkB phosphorylation and STAT3 (Tyr705) activation, suppressing NF-κB nuclear translocation and STAT3 transcriptional activity. EC-70124 reduces tumor growth and cancer stem cell (CSC) populations in prostate cancer cells and xenograft models. EC-70124 is promising for research of prostate cancer .

JMV594 RM26	Bombesin Receptor	Cancer
JMV594 (Compound RM 26) is a bombesin analogue with high affinity and antagonistic effect for gastrin releasing peptide receptor (GRPR).JMV594 can be used for the research of cancer, such as Prostate cancer .

TcO-ABX474 TcO-5	PSMA	Cancer
TcO-ABX474 (TcO-5) is a potent prostate-specific membrane antigen (PSMA) inhibitor with a K_d value of 6.1 nM. TcO-ABX474 inhibits prostate cancer cell growth and metastasis. TcO-ABX474 is promising for research of prostate cancer .

MLN 591 MLN2704 antibody	PSMA	Cancer
MLN 591 is a human monoclonal antibody (mAb) targeting PSMA. MLN 591 can be used in Prostate cancer research .

PSMA-1-SMCC	PSMA	Cancer
PSMA-1-SMCC is a selective binding agent targeting Prostate-Specific Membrane Antigen (PSMA). PSMA-1-SMCC is promising for research of targeted imaging for prostate cancer .

(R)-Zadavotide guraxetan (R)-PSMA I&T; (R)-PNT-2002	PSMA	Cancer
Zadavotide guraxetan (PSMA I&T; PNT-2002) is a prostate-specific membrane antigen (PSMA) inhibitor. Zadavotide guraxetan has antitumor activity and can be used in prostate cancer-targeted research .

Cat. No.	상품명

HY-L124

Anti-Prostate Cancer Compound Library

3,419 compounds

Cancer is one of the leading causes of mortality amongst world’s population, in which prostate cancer (PCa) is one of the most encountered malignancies among men. Several molecular mechanisms are involved in prostate cancer development and progression. These include common survival factors in prostate cancer (IGF-1), growth factors (TGF-α, EGF), Wnt, Hedgehog, NF-κB, and mTOR and other signaling pathways. These provide potential therapeutic target in prostate cancer treatment.

MCE offers a unique collection of 3,419 compounds with identified and potential anti-prostate cancer activity. MCE Anti-Prostate Cancer Compound Library is a useful tool for anti-prostate cancer drugs screening and other related research.

HY-L107

Anti-Cancer Natural Product Library

1,934 compounds

With features of enormous scaffold diversity and structural complexity, natural products (NPs) are the main sources of lead compounds and new drugs and play a highly significant role in the drug discovery and development process, especially for cancer and infectious diseases. A large number of natural products have been proven to have potential anti-tumor effects, mainly from plants, animals, Marine organisms and microorganisms. At present, derived than 60% of anti-tumor drugs come from natural sources, and they are widely used in breast, prostate and colon cancers.

MCE offers a unique collection of 1,934 natural products with validated anti-cancer activity. MCE anti-cancer natural product library is a useful tool for anti-tumor drugs screening and other related research.

Cat. No.	상품명	Type

HY-P3371

Ifinatamab deruxtecan

DS-7300a; MABX-9001a; I-DXd

Fluorescent Dyes

Ifinatamab deruxtecan (DS-7300a) is a B7-H3-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonal antibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects

HY-131498

MOCAc-PLGL(Dpa)AR

Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2

Fluorescent Dyes

MOCAc-PLGL (Dpa) AR (Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH₂) is a synthetic fluorescent substrate mainly used for in vitro enzymatic activity assays of MMP-7 (detection at 393 nm after excitation at 328 nm). MOCAc-PLGL (Dpa) AR is specifically cleaved and hydrolyzed by MMP-7 at the Gly-Leu peptide bond, allowing enzymatic activity to be monitored via fluorometry or HPLC (DMSO is usually added to ensure sufficient dissolution when determining kinetic parameters). MOCAc-PLGL (Dpa) AR is used to accurately evaluate the catalytic activity and pH dependence of recombinant mature human MMP-7 in vitro. MOCAc-PLGL (Dpa) AR is suitable for research on the mechanisms of tumor metastasis and invasion, particularly in fields such as prostate cancer, colon cancer, lung cancer and breast cancer .\n

HY-173639

AZD0516

Fluorescent Dyes

AZD0516 is a first-in-class antibody-drug conjugate (ADC) targeting six-transmembrane epithelial antigen of the prostate-2 (STEAP2). The anti-STEAP2 monoclonal antibody (mAb) is conjugated via interchain cysteines to a maleimide-reactive, β-glucuronidase-cleavable linker (HY-173635) bearing the topoisomerase 1 inhibitor, Exatecan (HY-13631). AZD0516 can be used for the study of prostate cancer .

HY-164729

FZ-AD005

Fluorescent Dyes

FZ-AD005 is a DLL3-targeting antibody-drug conjugate (ADC) with high selectivity, composed of the anti-DLL3 antibody FZ-A038 (HY-P990896), a dipeptide linker (Val-Ala), and DXd (HY-13631D). The K_d value of FZ-AD005 for human DLL3 ranges from 13.29 to 58.3 pmol/L. After binding to DLL3 on the cell surface, FZ-AD005 mediates endocytosis, and the payload DXd is released via cleavage by lysosomal cathepsins. DXd inhibits topoisomerase TopI to induce double-strand DNA breaks, cell cycle arrest and apoptosis, and FZ-AD005 exhibits bystander killing activity against adjacent DLL3-negative cells. FZ-AD005 shows stable circulation in vivo, has good tolerance and acceptable pharmacokinetic profiles in rats and cynomolgus monkeys, and effectively inhibits the growth of DLL3-expressing tumor cells. FZ-AD005 serves as a promising candidate molecule for research on small cell lung cancer and human neuroendocrine prostate cancer .

HY-145622

Mecbotamab vedotin

BA3011; CAB-Axl-ADC; CAB-anti-Axl-ADC

Fluorescent Dyes

Mecbotamab vedotin (BA3011) is a pH dependent antibody drug conjugate (ADC) targeting AXL. Mecbotamab vedotin can significantly inhibit AXL in DU145 cells and LCLC-103H cells and kills cells. Mecbotamab vedotin can be used for research on cancer such as lung cancer, pancreatic cancer and prostate cancer. The antibody component is Mecbotamab (HY-P9988), and the ADC toxin molecule is Monomethyl auristatin E (MMAE) (HY-15162) .

HY-D3347

DUPA-FITC

Fluorescent Dyes

DUPA-FITC is a fluorescent reagent targeting PSMA, which specifically binds to prostate cancer cells expressing PSMA without non-specific binding to normal blood cells. DUPA-FITC can label PSMA-expressing prostate cancer cells in whole blood, followed by internalization and trafficking to acidic intracellular endosomes, during which the fluorescence is quenched. When combined with flow cytometry and density gradient centrifugation enrichment, DUPA-FITC enables quantitative analysis of circulating tumor cells in peripheral blood samples from prostate cancer patients .

HY-D3189

5GluAF-2MeTG

Fluorescent Dyes

5GluAF-2MeTG is an activatable fluorescent probe targeting the glutamate carboxypeptidase (CP) activity of PSMA (Ex/Em=490/500-600 nm). After being hydrolyzed by PSMA, 5GluAF-2MeTG releases a cell membrane-permeable fluorescent product, and achieves fluorescence activation by disrupting donor-excited photoinduced electron transfer (d-PeT). 5GluAF-2MeTG enables fluorescence imaging of live PSMA-expressing prostate cancer cells in vitro and visualizes the carboxypeptidase activity of PSMA. 5GluAF-2MeTG can be used to detect prostate cancer regions in preclinical excised tissue specimens .

HY-D3353

PSMA-SulfoCy7

Fluorescent Dyes

PSMA-SulfoCy7 is a high-affinity imaging agent targeting PSMA/GCPII (with a K_i of 18.1 nM for human PSMA). PSMA-SulfoCy7 regulates PSMA-dependent NAAG hydrolysis. PSMA-SulfoCy7 exhibits excellent in vivo imaging capability, enabling clear visualization of PSMA-expressing tumors in xenograft models, with no obvious toxicity even at a dose of 87.9 mg/kg. PSMA-SulfoCy7 is widely used in prostate cancer-related studies .

HY-N0565AG

Doxycycline (hydrochloride)

Fluorescent Dyes

Doxycycline hydrochloride GMP is Doxycycline (hydrochloride) (HY-N0565A) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Doxycycline hydrochloride is an orally active highly lipophilic, tissue-permeable MMP inhibitor with broad-spectrum antibacterial activity. Doxycycline hydrochloride is also a semi-synthetic antibiotic with chelating properties, which blocks bacterial protein synthesis and inhibits extracellular matrix degradation through interactions with zinc and calcium atoms. Doxycycline hydrochloride also inhibits mitochondrial biogenesis, translation, and the expression of respiratory chain proteins. Doxycycline hydrochloride induces apoptosis, inhibits autophagy and EMT, downregulates stem cell markers, and activates the PI3K-AKT pathway, thereby effectively inhibiting the viability and proliferation of cancer cells such as breast cancer cells. Doxycycline hydrochloride also promotes the survival and self-renewal of embryonic stem cells and neural stem cells, and reduces the frequency of medium changes in culture. Doxycycline hydrochloride has been applied in studies related to breast cancer, prostate cancer, bladder cancer, and other cancers .

Cat. No.	상품명	Type

HY-125865

Casein

2 Publications Verification

Biochemical Assay Reagents

Casein is an orally active phosphoprotein that can be separated into various electrophoretic components, such as α₂-Casein, κ-Casein, β-casein, and γ-casein. Casein has also been blended and grafted with other polymers, cross-linkers, or monomers to improve its functional properties. Casein enhances calcium absorption and reduces the extent of fissure as well as smooth-surface caries. Casein promotes proliferation of prostate cancer. Casein has various applications in the paper, leather, textile, and food industries, serving as coatings, adhesives, and packaging materials .

HY-Y1883

Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant

Maximum Cited Publications

24 Publications Verification

Biochemical Assay Reagents

Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant is a non-denaturing detergent that solubilizes lipid membranes. Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant is commonly used in laboratories and is applied to vaccines at different stages of the manufacturing process. Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant is listed as an excipient in certain vaccines including split virus influenza vaccines. Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant is a nonionic surfactant. Polyethylene glycol mono(4-tert-octylphenyl) ether surfactant induces Apoptosis in prostate and colon cancer cell lines and reduces the infectivity of classic enveloped viruses such as WNV .

HY-113217

Cholesteryl oleate 1 Publications Verification	Biochemical Assay Reagents
Cholesteryl oleate is an ester compound formed from Cholesterol (HY-N0322) and Oleic acid (HY-N1446), which is involved in lipid transport, storage and cell membrane formation in living organisms. Cholesteryl oleate may serve as a potential biomarker for prostate cancer. Cholesteryl oleate can also prepare cationic solid lipid nanoparticles (SLNs) for efficient gene silencing .

HY-W054292

tert-Butyl-DCL (OtBu)KuE(OtBu)2	Biochemical Assay Reagents
Tert-Butyl-DCL is a PSMA inhibitor. Tert-Butyl-DCL Tert-Butyl-DCL can be used in the research of prostate cancer .

HY-W782083

p-SCN-Bn-NOTA trihydrochloride

Biochemical Assay Reagents

p-SCN-Bn-NOTA trihydrochloride is a macrocyclic chelator. p-SCN-Bn-NOTA trihydrochloride can be covalently coupled to molecules such as peptides through the thiocyanate group to form hexacoordinate copper (such as ⁶⁴Cu) complexes. p-SCN-Bn-NOTA trihydrochloride specifically binds to GRPR or EGFR highly expressed on the surface of tumor cells, mediating tumor enrichment of radioactive probes. p-SCN-Bn-NOTA trihydrochloride can be used to study malignant tumors expressing GRPR or EGFR, such as prostate cancer and colorectal cancer .

HY-Y1887

Cottonseed oil

Biochemical Assay Reagents

Cottonseed oil is an edible oil extracted from the seeds of cotton (Gossypium hirsutum). Its fatty acid composition includes 26-35% saturated fatty acids, 42-52% polyunsaturated fatty acids, and 18-24% monounsaturated fatty acids. Cottonseed oil is regarded as an Insecticide, as it is used to protect the trunks of apple trees from damage by the apple clearwing moth. Cottonseed oil possesses anti-inflammatory and cardioprotective properties. It also has extensive applications in many fields such as biofuels, animal husbandry, cosmetics, agriculture, and chemical industry .

HY-201263

p-SCN-Bn-TCMC	Biochemical Assay Reagents
p-SCN-Bn-TCMC is a bifunctional chelator. Its cyclen backbone binds Hg ²⁺, while its isothiocyanate group allows for conjugation to biomolecules. p-SCN-Bn-TCMC can be used in the research of prostate cancer .

HY-B1817A

Zinc acetate, 99.99% trace metals basis

Zinc(II) acetate, 99.99% trace metals basis

Biochemical Assay Reagents

Zinc (Zinc (II)) acetate, 99.99% trace metals basis is a heme oxygenase 1 (HO-1) activator and apoptosis inducer with cytotoxic and anticancer activities. Zinc acetate, 99.99% trace metals basis enhances HO-1 expression, alters the microRNA profile, and increases the level of caspase-cleaved cytokeratin 18. Zinc acetate, 99.99% trace metals basis also regulates the expression of Cdk2/cyclin E and interferes with cell cycle progression. Zinc acetate, 99.99% trace metals basis effectively inhibits cancer cell proliferation and induces their rapid death, with no significant cytotoxicity to non-tumor tissues. Zinc acetate, 99.99% trace metals basis has been widely used in studies related to hepatocellular carcinoma, prostate cancer, and other conditions .

HY-NP199

Bovine pituitary extract 1 Publications Verification	Biochemical Assay Reagents
Bovine pituitary extract is a bovine pituitary extract that can be used as a mitogenic supplement in serum-free growth media. Bovine pituitary extract is rich in growth factors. Bovine pituitary extract not only promotes the proliferation of corneal keratinocytes and maintains their phenotype, but also exerts significant antioxidant stress protective effects on human prostate epithelial cells .

HY-40351

4-Chloro-7H-pyrrolo[2,3-d]pyrimidine	Biochemical Assay Reagents
4-Chloro-7H-pyrrolo[2,3-d]pyrimidine is a nitrogen-containing heterocyclic organic synthesis intermediate that can be used for the synthesis of JAK and PKB/Akt inhibitors .

HY-W014141

5,6-O-Isopropylidene-L-ascorbic acid L-Ascorbic acid 5,6-acetonide	Biochemical Assay Reagents
5,6-O-Isopropylidene-L-ascorbic acid (L-Ascorbic acid 5,6-acetonide) is an organic compound and a derivative of L-ascorbic acid (vitamin C). 5,6-O-Isopropylidene-L-ascorbic acid inhibits biofilm formation by pathogenic bacteria. 5,6-O-Isopropylidene-L-ascorbic acid is applicable to studies related to bacterial infections .

HY-143209B

DSPE-PEG3400	Biochemical Assay Reagents
DSPE-PEG3400 is a phospholipid-PEG polymer conjugate that can be used in drug delivery applications. DSPE-PEG3400 serves as a material for preparing nanocarriers, which is used to prolong blood circulation time, enhance stability and improve encapsulation efficiency .

HY-155887

DSPE-PEG-Amine, MW 3400 ammonium

DSPE-PEG-NH2, MW 3400 ammonium

Biochemical Assay Reagents

DSPE-PEG-Amine (DSPE-PEG-NH2), MW 3400 ammonium is an amino-functionalized PEGylated phospholipid. It serves not only as a key component for preparing σ receptor-targeted liposomes (such as anisamide-modified lipids) but also as a starting material for synthesizing click chemistry- and tumor-targeted lipids including DSPE-PEG-DBCO (HY-155788) and DSPE-PEG2000-TCO (HY-170704). DSPE-PEG-Amine, MW 3400 ammonium effectively modulates the ζ potential of nanoparticles, enables complexation with nucleic acids or proteins to protect DNA from nuclease degradation, and supports ligand conjugation on the nanoparticle surface. It is used in studies related to DU-145 tumors, breast cancer, and other relevant research .

HY-158498

FA2 glycan (G0F)

FA2 N-linked oligosaccharide; F(6)A2 glycan

Biochemical Assay Reagents

FA2 glycan (G0F) (FA2 N-linked oligosaccharide; F(6)A2 glycan) is a core-fucosylated biantennary N-linked oligosaccharide that serves as a prostate cancer biomarker. The level of FA2 glycan (G0F) is higher in prostate cancer than in benign prostatic hyperplasia, and it is further elevated in advanced prostate cancer with a Gleason score ≥8 compared with both benign prostatic hyperplasia and low-/intermediate-risk prostate cancer. FA2 glycan (G0F) can be used in prostate cancer research .

HY-W008168

Quinoline-2-carboxaldehyde 2-Quinolinecarboxaldehyde	Biochemical Assay Reagents
Quinoline-2-carboxaldehyde (2-Quinolinecarboxaldehyde) is a quinoline derivative that serves as a synthetic precursor for Schiff base copper complexes. Quinoline-2-carboxaldehyde is applicable to research related to the synthetic design of biomaterials or organic compounds, such as fluorescent sensors .

HY-W088413A

DOTA-amide dihydrate	Biochemical Assay Reagents
DOTA-amide (dihydrate) is a Bifunctional Chelators (BFCs). DOTA-amide (dihydrate) binds to the Affibody molecule ZHER2:S1. Its complex binds specifically to HER2 and can be used to detect bone metastases, which are common in prostate cancer .

HY-131384

8,11,14-Eicosatriynoic acid

8,11,14-Icosatriynoic acid

Biochemical Assay Reagents

8,11,14-Eicosatriynoic Acid, as an inhibitor of prostaglandin, leukotriene biosynthesis, and arachidonic acid-induced platelet aggregation, blocks human 12-lipoxygenase (12-LO), cyclooxygenase (COX)and 5-lipoxygenase (5-LO) with IC50 values of 0.46 μM, 14 μMand 25 μM, respectively. In addition, 8,11,14-Eicosatriynoic Acid inhibits the action of slow-reacting substances of allergic reactions, with IC50 value of 10 μM. Lipoxygenase is widely found in fungi, plants and animals. 12-LO involves in many important disease states and may play a role in oxidative glutamate toxicity. COX enzymes play complex roles in human physiology and pathology involving the neuronal, immune, renal, cardiovascular, gastrointestinal and reproductive systems. COX enzymes are blocked by aspirin and a variety of other NSAIDs, which makes them clinically important. 5-LO involves in cancer pathology. It is expressed by a variety of cancer cells, including colon, lung, breast, and prostate cancers, and promotes cancer cell growth and neovascularization . 8,11,14-Eicosatriynoic acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-N0565AG

Doxycycline (hydrochloride)

Biochemical Assay Reagents

Cat. No.	상품명	Target	Research Area

HY-16168A

Degarelix Maximum Cited Publications 11 Publications Verification FE 200486 free base	GnRH Receptor Apoptosis	Endocrinology Cancer
Degarelix acetate (FE 200486) is a decapeptide that shows high affinity/selectivity to human gonadotropin-releasing hormone (GnRH) receptor (IC₅₀ = 3 nM). Degarelix acetate Degarelix acetate (FE 200486) is used for the research of prostate cancer .

HY-13673A

Goserelin acetate 1 Publications Verification ICI-118630 acetate	GnRH Receptor Apoptosis	Endocrinology Cancer
Goserelin acetate (ICI-118630 acetate), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin acetate can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer .

HY-P1416

Foxy-5 5+ Cited Publications	Wnt	Cancer
Foxy-5, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model .

HY-P3229

SN52 2 Publications Verification	NF-κB	Cancer
SN52 is a potent, competitive, and cell-permeable inhibitor of NF-κB2. SN52 is a variant of the SN50 peptide and inhibits the nuclear translocation of p52-RelB heterodimers. SN52 has a strong radiosensitization effect on prostate cancer cells. SN52 can be used for cancer research .

HY-134434

Z-Arg-Arg-AMC hydrochloride 1 Publications Verification	Cathepsin Fluorescent Dye	Others
Z-Arg-Arg-AMC hydrochloride is a highly selective fluorescent Cathepsin B substrate. Z-Arg-Arg-AMC hydrochloride can be hydrolyzed by Cathepsin B to produce a fluorescent product for enzyme activity detection .

HY-20167A

H-Glu(OtBu)-OtBu hydrochloride	Neurokinin Receptor	Cancer
H-Glu(OtBu)-OtBu hydrochloride is a key intermediate that can be used to synthesize prostate-specific membrane antigen (PSMA) targeting probes. H-Glu(OtBu)-OtBu hydrochloride can reduce nonspecific background binding through negatively charged linkers, improve tumor/background contrast, and can be used in prostate cancer PET/SPECT imaging studies .

HY-P2161B

TAK-683 acetate 4 Publications Verification	Kisspeptin Receptor	Cancer
TAK-683 acetate is a potent full KISS1 receptor (KISS1R) agonist (IC₅₀=170 pM) with improved metabolic stability. TAK-683 acetate is a nonapeptide metastin analog, exhibits agonistic activities to KISS1R with EC₅₀ values of 0.96 nM and 1.6 nM for human and rat, respectively . TAK-683 acetate depletes GnRH in the hypothalamus and reduces plasma FSH, LH, and testosterone levels in vivo, it has the potential for the study of hormone-dependent prostate cancer .

HY-13534

Abarelix 1 Publications Verification R3827; PPI 149	GnRH Receptor	Endocrinology Cancer
Abarelix (R3827; PPI 149) is a potent gonadotrophin-releasing hormone (GnRH) antagonist, used for prostate cancer treatment.

HY-P2284

AD 01 2 Publications Verification	Transmembrane Glycoprotein	Cancer
AD 01, a 24 amino acid peptide of FKBPL (FK506-binding protein like), possesses potent anti-angiogenic activity. AD 01 bind to the CD44 receptor and inhibit tumour cell migration in a CD44 dependant manner .

HY-P5284

RALA peptide	Peptides	Others
RALA peptide is a cationic amphiphilic delivery agent targeting cell membranes, which forms nanoparticles through electrostatic interactions with anionic drugs. RALA peptide has pH-responsive binding properties, which can enhance the α-helical conformation in an acidic environment and destroy the endosomal membrane, promote the release of drugs into the cytoplasm, and exert efficient intracellular delivery activity. RALA peptide can be used in cancer research (enhancing the activity of bisphosphonates against prostate cancer and breast cancer cells) and bone tissue engineering (promoting osteoblast collagen deposition and extracellular matrix mineralization) .

HY-P10284

S7	Interleukin Related VEGFR Apoptosis	Cardiovascular Disease Cancer
S7 is an inhibitory polypeptide targeting IL-6R, which specifically binds to IL-6R and its A chain (gp80/IL-6RA) to block its signal transduction. S7 inhibits IL-6-mediated anti-apoptosis (apoptosis), angiogenesis and the expression of VEGF-A, blocks related survival signaling pathways, and enhances the sensitivity of cancer cells to chemotherapeutic drugs. S7 can be applied to the research of related diseases such as cervical cancer, multiple myeloma, Kaposi's sarcoma, prostate cancer and basal cell carcinoma .

HY-P3668

[D-Lys6]-LH-RH	GnRH Receptor	Endocrinology Cancer
[D-Lys6]-LH-RH is a Luteinizing-hormone-releasing hormone (LHRH) analogue. [D-Lys6]-LH-RH acts as a GnRH receptor agonist .

HY-P1654

A20FMDV2	Integrin	Cancer
A20FMDV2 is a highly selective αvβ6 integrin inhibitor with human IC₅₀ values of 3 nM and binds with at least 1000-fold selectivity over other RGD-binding integrins. A20FMDV2 binds to the integrin’s RGD-binding site, induces rapid integrin internalization, and delays post-internalization integrin recycling to the cell surface. A20FMDV2 can be used for the research of pancreatic cancer, breast cancer, colorectal cancer, ovarian cancer, oral squamous cell carcinoma .

HY-P10387

RSM3 1 Publications Verification	METTL3 Apoptosis MDM-2/p53 NF-κB Caspase	Cancer
RSM3 is a METTL3-METTL14 complex inhibitor with a K_d of 3.10 μM for the METTL3-METTL14 complex. RSM3 reduces the m ⁶A modification level of SLC31A1 and the global RNA methylation level. RSM3 upregulates programmed cell death-related genes, enhances cell apoptosis, inhibits pro-cancer signals and suppresses tumor growth. RSM3 is applicable to the research of preeclampsia and cancer .

HY-P5990

Prostate Specific Antigen Substrate	PSMA	Cancer
Prostate Specific Antigen Substrate is a highly specific fluorescent peptide substrate can be used for measuring prostate-specific antigen (PSA) enzymatic activity .

HY-P6825

PNT2001 LY4181530; PSMA-62	PSMA	Cancer
PNT2001 (LY4181530) is a potent prostate specific membrane antigen (PSMA) ligand with an IC₅₀ of 3.1 nM. PNT2001 can improve cellular internalization. 177Lu- and 225Ac-labeled PNT2001 can be used in prostate cancer research .

HY-P5290

HYNIC-PSMA	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
HYNIC-PSMA is a ligand for molecular imaging of tumors. Hynic-psma consists of two components: HYNIC (6-hydrazinonicotinamide) and PSMA (Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules, such as ¹⁸⁸Re-HYNIC-PSMA. PSMA is a membrane antigen that is specifically expressed on the surface of prostate cancer cells. HYNIC-PSMA can be used in prostate cancer research . HYNIC-PSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P0013

Antide D-21074; ORF 23541	GnRH Receptor	Cancer
Antide (D-21074) is a potent LHRH antagonist. Antide also can be used for the research of prostatic cancer .

HY-P0056A

Histrelin acetate	GnRH Receptor	Cancer
Histrelin acetate, a GnRH analogue, is a GnRH Receptor agonist. Histrelin acetate increases serum luteinising hormone (LH), follicle stimulating hormone (FSH) and testosterone levels. Histrelin acetate can be used in the research of prostate cancer, endometriosis .

HY-P1416A

Foxy-5 TFA 5+ Cited Publications	Wnt	Cancer
Foxy-5 TFA, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 TFA triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 TFA effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model .

HY-P1793

α-Casein (90-95)	Opioid Receptor Biochemical Assay Reagents	Neurological Disease Inflammation/Immunology Cancer
α-Casein (90-95) is a partial agonist of opioid receptors and a copper ion ligand, with opioid activity. α-Casein (90-95) inhibits the secretion of β-hexosaminidase by rat peritoneal mast cells (PMC) with IC₅₀= 0.1 μM. α-Casein (90-95) inhibits the proliferation of prostate cancer cells LNCaP, DU145, and PC3 with IC₅₀ of 0.94 nM, 137 nM, and 6.92 nM, respectively. α-Casein (90-95) activates G_i-like proteins through a membrane-assisted, receptor-independent pathway, or reversibly binds to opioid receptors, inducing intracellular calcium release and conformational changes, and exerts the activity of promoting mast cell secretion and inhibiting tumor cell proliferation. α-Casein (90-95) can be used in the study of the mechanisms of allergic diseases and prostate cancer .

HY-P10422A

Multi-Leu peptide triacetate ML-peptide, Multi-Leucine (ML)-peptide triacetate	Autophagy	Cancer
Multi-Leu peptide (ML-peptide) triacetate is a potent inhibitor of PACE4 (K_i=22 nM). Multi-Leu peptide triacetate can competitively bind to the active site of PACE4 by simulating the substrate sequence of PACE4, thereby inhibiting its catalytic activity. Multi-Leu peptide triacetate can be used to study the specific mechanism of PACE4 in the development of prostate cancer .

HY-P10896

NOTA-P2-RM26	Bombesin Receptor	Cancer
NOTA-P2-RM26 is an antagonist of Bombesin (HY-P0195) analogs, and the gastrin-releasing peptide receptor (GRPR/BB2) is a molecular target for prostate cancer visualization. NOTA-P2-RM26 is labeled with ¹¹¹In and ⁶⁸Ga for prostate cancer imaging studies using PET and SPECT/CT .

HY-P11211A

D2A21 TFA	Bacterial	Infection Cancer
D2A21 TFA is an antimicrobial peptide with significant antimicrobial activity against Pseudomonas and bactericidal effect on burn scabs. D2A21 TFA has antitumor activity and can be used in prostate cancer research .

HY-13673

Goserelin ICI 118630	GnRH Receptor Apoptosis	Endocrinology Cancer
Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer .

HY-P10740

CBP-1018	Peptide-Drug Conjugates (PDCs) PSMA Folate Receptor (FR)	Cancer
CBP-1018 is a PDC (peptide-drug conjugate) formed by conjugating Monomethyl auristatin E (HY-15162) to a dual-targeting ligand of FLOR1/PSMA (prostate-specific membrane antigen) via a linker (HY-78738). CBP-1018 binds to FLOR1 and prostate-specific membrane antigen (PSMA). CBP-1018 is applicable to the research of solid tumors and metastatic castration-resistant prostate cancer .

HY-P4516

Z-Phe-Leu-Glu-pNA	Peptides	Cancer
Z-Phe-Leu-Glu-pNA is a chromogenic substrate for glutamyl endopeptidases. Z-Phe-Leu-Glu-pNA has been used as a synthetic substrate in the study of proteolytic enzymes, including trypsin treatment, subtilisin and chymotrypsin. Z-Phe-Leu-Glu-pNA plays an important role in hormone disorders such as prostate cancer and breast cancer .

HY-P5831

Biotin-H10	Peptides MDM-2/p53	Cancer
Biotin-H10 is a specific anterior gradient homolog 2 (AGR2) inhibitor with a K_D of 6.4 nM. Biotin-H10 inhibits cancer cells viability .

HY-16498

Tigapotide PCK-3145	Apoptosis PTHR	Metabolic Disease Cancer
Tigapotide (PCK-3145) is a synthetic 15-mer peptide derived from prostate-secretory protein, and acts as an antineoplastic agent. Tigapotide inhibits tumor growth, experimental bone metastasis, and malignancy-associated hypocalcemia. Tigapotide induces apoptosis in prostate cancer cells and tumors, and suppresses the growth of prostate cancer cells. Tigapotide inhibits the production of parathyroid hormone-related protein (PTHrP) in tumors and plasma. Tigapotide reduces plasma calcium levels in hypercalcemic tumor-bearing rats. Tigapotide is applicable for the research of prostate cancer and malignancy-associated hypercalcemia .

HY-P0056

Histrelin	GnRH Receptor	Cancer
Histrelin, a GnRH analogue, is a GnRH Receptor agonist. Histrelin increases serum luteinising hormone (LH), follicle stimulating hormone (FSH) and testosterone levels. Histrelin can be used in the research of prostate cancer, endometriosis .

HY-P5292A

HYNIC-iPSMA TFA	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
HYNIC-iPSMA TFA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA TFA has excellent specificity and sensitivity . HYNIC-iPSMA TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10387A

RSM3 TFA 1 Publications Verification	METTL3 Apoptosis	Cancer
RSM3 TFA is a METTL3-METTL14 complex inhibitor with a K_d of 3.10 μM for the METTL3-METTL14 complex. RSM3 TFA reduces the m ⁶A modification level of SLC31A1 and the global RNA methylation level. RSM3 TFA upregulates programmed cell death-related genes, enhances cell apoptosis, inhibits pro-cancer signals and suppresses tumor growth. RSM3 TFA is applicable to the research of preeclampsia and cancer .

HY-P10781

PSMA-D5	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
PSMA-D5 has a binding affinity for PSMA with a K_i of 0.21 nM and can be used for PSMA tracing after radiolabeling. PSMA-D5 ([68Ga]-labeled) contains a DOTA chelator, allowing convenient labeling with therapeutic radionuclides such as 177Lu and 225Ac. PSMA-D5 ([68Ga]-labeled) shows excellent pharmacokinetic properties, exhibiting remarkable tumor uptake in 22Rv1 tumors . PSMA-D5 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P3668A

[D-Lys6]-LH-RH TFA	GnRH Receptor	Endocrinology Cancer
[D-Lys6]-LH-RH TFA is a Luteinizing-hormone-releasing hormone (LHRH) analogue. [D-Lys6]-LH-RH TFA acts as a GnRH receptor agonist .

HY-P5413

[Lys3]-Bombesin	Cholecystokinin Receptor	Others
[Lys3]-Bombesin is a biological active peptide. (PET (Positron Emission Tomography) imaging of [Lys3]-bombesin is able to detect gastrin-releasing peptide receptor (GRPR) positive prostate cancer. An immunoconjugate of [Lys3]-bombesin and corresponding monoclonal antibody can specifically induce (CD64)-dependent monocyte and neutrophil-mediated lysis of small cell carcinoma.)

HY-P2496

Endothelin 1 (swine, human), Alexa Fluor 488-labeled	Endothelin Receptor Fluorescent Dye NF-κB COX Prostaglandin Receptor Apoptosis TNF Receptor Interleukin Related MMP	Cardiovascular Disease Inflammation/Immunology Cancer
Endothelin 1 (swine, human), Alexa Fluor 488-labeled is an Endothelin-1 conjugated with Alexa Fluor 488 (HY-D1304). Endothelin-1 is an endogenous vasoconstrictor and agonist of ETA/ETB receptor. Endothelin 1 (swine, human) exerts effects including promoting mitosis, angiogenesis, tumor invasion and metastasis, and inhibiting apoptosis. Endothelin 1 (swine, human) induces inflammation and oxidative stress by activating the NF-κB pathway. Endothelin 1 (swine, human), Alexa Fluor 488-labeled is specifically designed for fluorescence imaging, flow cytometry or receptor localization studies, and can be used in research related to sepsis, atherosclerosis, systemic inflammatory response syndrome, cancer and congestive heart failure .

HY-P11352

JMV594 RM26	Bombesin Receptor	Cancer
JMV594 (Compound RM 26) is a bombesin analogue with high affinity and antagonistic effect for gastrin releasing peptide receptor (GRPR).JMV594 can be used for the research of cancer, such as Prostate cancer .

HY-P5292

HYNIC-iPSMA	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
HYNIC-iPSMA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA has excellent specificity and sensitivity . HYNIC-iPSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-178489

BGC1614	Nectin-4	Cancer
BGC1614 is a Nectin-4-targeting bicyclic toxin conjugate (BTC) belonging to the category of peptide-drug conjugates (PDCs). BGC1614 exhibits strong targeted binding ability to Nectin-4, with an K_D of 3.859 × 10 ^-7 M. BGC1614 exhibits superior antitumor efficacy in nude mice bearing PC-3 and N87 tumor xenografts. BGC1614 can be used for research related to Nectin-4-overexpressing tumors (such as prostate cancer, gastric cancer) .

HY-P10759

DTS-201 sodium	Peptide-Drug Conjugates (PDCs) Aminopeptidase	Cancer
DTS-201 sodium (CPI-0004Na) is a peptidic prodrug of Doxorubicin (HY-15142A). DTS-201, comprising the tetrapeptide portion, is cleaved by endopeptidases in the tumor environment to produce metabolites that subsequently enter the cell and are converted to active Doxorubicin. DTS-201 shows antitumoral efficacy in tumor xenograft models of prostate, breast, and lung cancer .

HY-P2161

TAK-683	Kisspeptin Receptor	Cancer
TAK-683 is a potent full KISS1 receptor (KISS1R) agonist (IC₅₀=170 pM) with improved metabolic stability. TAK-683 is a nonapeptide metastin analog, exhibits agonistic activities to KISS1R with EC₅₀ values of 0.96 nM and 1.6 nM for human and rat, respectively . TAK-683 depletes GnRH in the hypothalamus and reduces plasma FSH, LH, and testosterone levels in vivo, it has the potential for the study of hormone-dependent prostate cancer .

HY-P1813

PSA1 (141-150) PSA-Peptide	Prostaglandin Receptor	Cancer
PSA1 (141-150), a prostate specific antigen 1 peptide, is used in the immunotherapy of cancer experiments .

HY-P4144

Onvitrelin ucalontide Phor18-LHRH (338613); EP-100	GnRH Receptor	Endocrinology Cancer
Onvitrelin ucalontide ([Phor18-LHRH (338613)]) is an analogue of luteinizing hormone releasing hormone (LHRH) with antineoplastic activity. Onvitrelin ucalontide is a peptide with sequences of KFAKFAKKFAKFAKKFAKQHWSYGLRPG. Onvitrelin ucalontide effectively inhibits breast cancer, ovarian cancer and prostate cancer xenografts in mouse model .

HY-P11310

PSMA-1-SMCC	PSMA	Cancer
PSMA-1-SMCC is a selective binding agent targeting Prostate-Specific Membrane Antigen (PSMA). PSMA-1-SMCC is promising for research of targeted imaging for prostate cancer .

HY-P10951

(R)-Zadavotide guraxetan (R)-PSMA I&T; (R)-PNT-2002	PSMA	Cancer
Zadavotide guraxetan (PSMA I&T; PNT-2002) is a prostate-specific membrane antigen (PSMA) inhibitor. Zadavotide guraxetan has antitumor activity and can be used in prostate cancer-targeted research .

HY-P11443

SRC2-2 peptide	Androgen Receptor	Cancer
SRC2-2 peptide is a a coactivator-derived mimic targeting androgen receptor (AR) ligand. SRC2-2 peptide is promising for research of prostate cancer .

HY-16375

Ozarelix D-63153	GnRH Receptor Apoptosis	Cancer
Ozarelix (D-63153) is a GnRH antagonist. Ozarelix induces cell apoptosis and arrests cell in G2/M phase. Ozarelix can be used in the research of prostate cancer .

HY-16168B

Degarelix acetate hydrate FE 200486 acetate hydrate	GnRH Receptor Apoptosis	Endocrinology Cancer
Degarelix acetate hydrate (FE 200486 acetate hydrate) is a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR/LHRHR) antagonist. Degarelix acetate hydrate can be used for prostate cancer research .

HY-105173

Teverelix EP 24332	GnRH Receptor Histamine Receptor	Endocrinology Cancer
Teverelix (EP 24332) is a GnRH antagonist. Teverelix binds competitively and reversibly to GnRH receptors, thereby suppressing the release of LH and FSH. Teverelix can be used in the research of prostatic hyperplasia, endometriosis, and prostate cancer .

HY-P11007

β-catenin inhibitory peptoid	β-catenin Wnt Androgen Receptor	Cancer
β-catenin inhibitory peptoid (compound 13) inhibits the β-catenin:TCF interaction with an IC₅₀ of 5.44 µM. β-catenin inhibitory peptoid inhibits both Wnt (IC₅₀ of 0.105 µM) and androgen receptor (AR)-signaling (IC₅₀ of 1.02 µM) in prostate cancer cell lines. β-catenin inhibitory peptoid markedly diminishes cell proliferation of prostate cancer cell lines .

Cat. No.	상품명	Target	Research Area	Image

HY-P99239

Rosopatamab HUJ-591; TLX591	PSMA Radionuclide-Drug Conjugates (RDCs)	Cancer
Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 ( ¹⁷⁷Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency .

HY-P3371

Ifinatamab deruxtecan DS-7300a; MABX-9001a; I-DXd	Antibody-Drug Conjugates (ADCs) Topoisomerase Apoptosis	Cancer
Ifinatamab deruxtecan (DS-7300a) is a B7-H3-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonal antibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects

HY-P991015

Pasritamig JNJ-78278343; KLCB-245	CD3	Cancer
Pasritamig (JNJ-78278343; KLCB-245) is a bispecific T-cell engager (BiTE) that targets the complex of human kallikrein KLK2 and CD3 receptor. Pasritamig redirects the cytotoxicity of T cells to KLK2-expressing tumor cells and induces T cell-mediated lysis of KLK2-expressing prostate cancer cells. Administered via subcutaneous injection, subcutaneous infusion or intravenous infusion, Pasritamig exhibits antitumor activity against metastatic castration-resistant prostate cancer. Pasritamig has a safety profile with an extremely low incidence of cytokine release syndrome and can be safely administered in an outpatient setting. Pasritamig is applicable to the research of metastatic castration-resistant prostate cancer .

HY-P990673

Vandortuzumab DSTP-3086S Antibody; RG-7450 Antibody	ADC Antibody Transmembrane Glycoprotein Mitosis	Cancer
Vandortuzumab (DSTP-3086S Antibody; RG-7450 Antibody) is a humanized anti-STEAP1 IgG1 antibody and antimitotic agent that can be conjugated with MMAE (HY-15162) to form the antibody-drug conjugate (ADC) Vandortuzumab vedotin. Vandortuzumab vedotin specifically binds to STEAP1 and drives internalization of the complex, releasing the MMAE (HY-15162) payload intracellularly. After binding to tubulin, MMAE inhibits cell division and induces cell death. Vandortuzumab exhibits antitumor activity in preclinical xenograft models of prostate cancer and can be used for research related to metastatic castration-resistant prostate cancer (mCRPC) .

HY-P990688

Xaluritamig AMG-509	CD3	Cancer
Xaluritamig (AMG-509) is a bispecific T cell engager and cytolytic agent with a K_d of 27.6 nM for human CD3ε. Xaluritamig binds to CD3ε via an anti-CD3 single-chain variable fragment (scFv) domain, and to STEAP1 via a bispecific anti-STEAP1 antigen-binding fragment (Fab) domain, thereby recruiting and activating T cells and forming a bridge between T cells and STEAP1-expressing cancer cells. Xaluritamig induces T cell-mediated redirected cytotoxicity, tumor cell lysis, cytokine release, CD8 ⁺ T cell activation and expansion, as well as tumor stasis or regression. Xaluritamig contains an Fc domain with no effector function, which prolongs serum half-life, exhibits only minimal activity against cells with low STEAP1 expression and normal cells, and shows extremely low target-related off-tumor toxicity in cynomolgus monkeys. Xaluritamig is used in STEAP1×CD3 XmAb 2+1 immunotherapy and in research on metastatic castration-resistant prostate cancer and Ewing sarcoma .

HY-P990106

Anti-Mouse VEGFR-2 Antibody (DC101)	VEGFR Apoptosis	Inflammation/Immunology Cancer
Anti-Mouse VEGFR-2 Antibody (DC101) is a rat anti-mouse VEGFR2 monoclonal antibody. Anti-Mouse VEGFR-2 Antibody (DC101) inhibits tumor angiogenesis by blocking the binding of VEGF and VEGFR2. Anti-Mouse VEGFR-2 Antibody (DC101) promotes immune cell infiltration and induces tumor cell apoptosis. Anti-Mouse VEGFR-2 Antibody (DC101) can be used for researches on various types of cancer such as melanoma, lung cancer and breast cancer .

HY-P991503

Anti-STEAP2 Antibody AZD0516 antibody	ADC Antibody	Cancer
Anti-STEAP2 Antibody (AZD0516 antibody) is an antibody targeting six-transmembrane epithelial antigen of the prostate 2 (STEAP2). Anti-STEAP2 Antibody can be used for the synthesis of the ADC molecule AZD0516 (HY-173639). Anti-STEAP2 Antibody can be used in the research of prostate cancer .

HY-P99802

Pasotuxizumab 1 Publications Verification BAY 2010112; AMG 212; MT112	CD3	Cancer
Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with K_Ds of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .

HY-P99517

Voxalatamab JNJ-63898081; JNJ-081	CD3 PSMA	Cancer
Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody targeting PSMA and CD3. Voxalatamab attacks PSMA-expressing tumor cells by activating T cells. Voxalatamab has anticancer activity and is being studied for the treatment of solid tumors such as prostate cancer .

HY-P99188

Carlumab 4 Publications Verification CNTO 888	CCR	Cancer
Carlumab (CNTO 888) is a human anti-CCL2 (chemokine ligand 2) monoclonal antibody. Carlumab binds and neutralises profibrotic activities of human CCL2. Carlumab inhibits tumor growth by reducing macrophage infiltration and decreasing tumor microvascular density. Carlumab can be used for the research of cancer, suah as prostate cancer .

HY-P9992

Pelgifatamab BAY-2315497; PSMA-TTC	PSMA Apoptosis	Cancer
Peligifatamab is a PSMA-targeted α-radioimmunoconjugate with an EC₅₀ of 1.2 nM against human targets. Peligifatamab induces DNA damage, DNA double-strand breaks, cell cycle arrest and apoptosis (Apoptosis) in PSMA-positive prostate cancer cells. Peligifatamab reduces cell viability in a manner dependent on cellular PSMA expression levels. Peligifatamab inhibits tumor growth and tumor-induced abnormal bone growth in prostate cancer bone metastasis models. Peligifatamab exhibits antitumor efficacy in subcutaneous prostate cancer models and xenograft models. Peligifatamab can be used for the research of metastatic castration-resistant prostate cancer .

HY-P99189

Cixutumumab IMC-A12; NSC742460	IGF-1R	Cancer
Cixutumumab (IMC-A12) is a human anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer .

HY-P9916

Sarilumab Anti-Human IL6Rα, Human Antibody	Interleukin Related STAT Apoptosis	Inflammation/Immunology Cancer
Sarilumab is a monoclonal antibody targeting IL6 that binds to IL6R and blocks the binding of IL6, thereby inhibiting the activation of the downstream *STAT3* phosphorylation signaling pathway. In tumor cells with active *IL6/STAT3* signaling pathways, Sarilumab induces Apoptosis and inhibits cell growth. Sarilumab is applicable to research related to prostate cancer, lung cancer and rheumatoid arthritis .

HY-P990627

Anti-EphA2 Antibody (1C1) MEDI-547 antibody	ADC Antibody Ephrin Receptor	Cancer
Anti-EphA2 Antibody (1C1) (MEDI-547 antibody) is an anti-EphA2 monoclonal antibody. Anti-EphA2 Antibody (1C1) can induce degradation of EphA2 protein. Anti-EphA2 Antibody (1C1) conjugated with McMMAF (HY-15578) can form an antibody-conjugated drugs, which has potent antitumor activity. Anti-EphA2 Antibody (1C1) can be used for the research of cancer, such as prostate cancer and glioma .

HY-P991577

DS-8895 DS-8895A	Ephrin Receptor	Cancer
DS-8895(DS-8895A) is an anti-EphA2 monoclonal antibody with specific binding to EphA2 receptors and EphA2-expressing cells. DS-8895, when conjugated with ⁸⁹Zr, ¹¹¹In, or ¹²⁵I, supports molecular imaging of EphA2 expression in xenograft models. DS-8895 allows noninvasive measurement of EphA2 expresssion in tumors in vivo. .

HY-P99183

Abituzumab EMD 525797; DI17E6	Integrin	Cancer
Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonal antibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer .

HY-P99217

Rilotumumab AMG 102	c-Met/HGFR	Cancer
Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research .

HY-P990255

Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) 1 Publications Verification	CXCR	Inflammation/Immunology Cancer
Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) is an anti-mouse CXCL9/MIG IgG monoclonal antibody. Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) can reduce tumor infiltration of CD8 ⁺ cytotoxic T cells (CTLs). Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) can prolong the survival of transplanted hearts. Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) can be used for researches on immunology and cancer such as prostate cancer .

HY-P99714

Lorigerlimab MGD019	PD-1/PD-L1 CTLA-4	Cancer
Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .

HY-P991723

Varsetatug CX-2051 antibody	ADC Antibody Transmembrane Glycoprotein	Cancer
Varsetatug (CX-2051 antibody) is a humanized IgG1κ monoclonal antibody inhibitor targeting EpCAM/TROP1/CD326. Varsetatug serves as the antibody component of the ADC compound CX-2051. It can be used in research on cancers including breast cancer, prostate cancer and ovarian cancer .

HY-P991359

Anti-FOLH1/PSMA Antibody (J591) MEDI3726 antibody; ADCT-401 antibody	PSMA ADC Antibody	Cancer
Anti-FOLH1/PSMA Antibody (J591) (MEDI3726 antibody) is a human monoclonal antibody (mAb) targeting FOLH1/PSMA. Anti-FOLH1/PSMA Antibody (J591) can be used in Prostate cancer research .

HY-P990279

Anti-Mouse CD276/B7-H3 Antibody (MJ18)	CD276/B7-H3 Apoptosis STAT	Inflammation/Immunology Cancer
Anti-Mouse CD276/B7-H3 Antibody (MJ18) is a rat-derived anti-mouse CD276/B7-H3 IgG1 monoclonal antibody. Anti-Mouse CD276/B7-H3 Antibody (MJ18) can inhibit CD276/B7-H3 and induce tumor cell apoptosis. Anti-Mouse CD276/B7-H3 Antibody (MJ18) enhances anti-tumor immune response by reducing immunosuppressive cells and promoting T cell activation. Anti-Mouse CD276/B7-H3 Antibody (MJ18) can be used for research on cancer such as breast cancer and prostate cancer .

HY-P991708

Olsutamig REGN-4336	PSMA CD3	Cancer
Olsutamig is a bivalent humanized IgG4κ monoclonal antibody inhibitor targeting FOLH1/PSMA and CD3E. Olsutamig simultaneously binds to PSMA on the tumor cell surface and CD3E on the T cell surface, markedly activating T cells and thereby specifically killing prostate cancer cells .

HY-P991360

MLN 591 MLN2704 antibody	PSMA	Cancer
MLN 591 is a human monoclonal antibody (mAb) targeting PSMA. MLN 591 can be used in Prostate cancer research .

HY-P991292

AB-3A4	ADC Antibody	Cancer
AB-3A4 is a human IgG1 monoclonal antibody (mAb) targeting KAAG1. AB-3A4 can be used in the study of ovarian cancer, triple-negative breast cancer, and prostate cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991243

MP-RM-1	EGFR Akt	Cancer
MP-RM-1 is an antibody-based, non-competitive ErbB-3 inhibitor with a K_d value of 32.7 nM. MP-RM-1 inhibits both ligand-dependent and ligand-independent ErbB-3 activation, blocks ErbB-2/ErbB-3 heterodimerization, induces ErbB-3 internalization and degradation, and suppresses the phosphorylation of downstream Akt. MP-RM-1 exerts its antagonistic effect through a non-competitive mechanism. MP-RM-1 inhibits tumor growth in melanoma and prostate cancer xenograft models in nude mice and reduces the proliferative activity of tumor cells .

HY-P991332

JAB-BX102	CD73	Cancer
JAB-BX102 is a human monoclonal antibody (mAb) targeting NT5E/CD73. JAB-BX102 can be used in the study of cancers such as breast cancer, pancreatic cancer, and prostate cancer .

HY-P991576

Anti-CD326/EPCAM Antibody (3622W94)	Transmembrane Glycoprotein	Cancer
Anti-CD326/EPCAM Antibody (3622W94) is a humanized antibody expressed in CHO cells, targeting EpCAM/TROP1/CD326. Anti-CD326/EPCAM Antibody (3622W94) can be used for epithelial cancers research, such as pancreatic, prostate and breast cancer.

HY-P99881

Rolinsatamab talirine ABBV 176	Antibody-Drug Conjugates (ADCs)	Cancer
Rolinsatamab talirine (ABBV 176) is a prolactin receptor (PRLR)-targeting antibody-drug conjugate (ADC), compoused of Rolinsatamab (HY-P99238) and SGD-1882 (HY-101127). Rolinsatamab talirine binds to PRLR to deliver a cytotoxin to tumor cells. Rolinsatamab talirine induces DNA damage, and exhibits cytotoxicity against multiple breast tumor models, including triple negative and low PRLR-expressing models. Rolinsatamab talirine demonstrates enhanced anti-tumor activity in several breast cancer models. Rolinsatamab talirine can be used for the research of breast cancer, hepatocellular carcinoma, ovarian cancer, endometrial cancer, prostate cancer, colorectal cancer, adrenocortical carcinoma, and solid tumors .

HY-P991330

BMS-986179	CD73	Cancer
BMS-986179 is a human monoclonal antibody (mAb) targeting NT5E/CD73. BMS-986179 inhibits CD73 enzymatic activity in tumor vasculature and tumor cells. BMS-986179 can be used in advanced solid tumors research .

HY-P991414

FGI-1011A6	HIV	Infection Cancer
FGI-1011A6 is a human monoclonal antibody (mAb) targeting TSG101. FGI-1011A6 can be used in Prostate cancer and Viral infections research .

HY-P991410

5T4_0108 MEDI0641 antibody	Wnt	Cancer
5T4_0108 (MEDI0641 antibody) is a human monoclonal antibody (mAb) targeting TPBG. 5T4_0108 can be used in breast and prostate cancer research .

HY-P991650

MDX1201	PSMA	Cancer
MDX1201 is a humanized monoclonal antibody targeting PSMA1/7. MDX1201 conjugated with a fluorescent dye AlexaTM488 can be used as a probe for near-infrared fluorescence imaging (NIRF) imaging of prostate cancer .

HY-P99528

Vandortuzumab vedotin DSTP 3086S; RG 7450; MSTP2109A	Antibody-Drug Conjugates (ADCs)	Cancer
Vandortuzumab vedotin (DSTP 3086S; RG 7450) is a STEAP1-targeted antibody-drug conjugate (ADC). Vandortuzumab vedotin binds specifically to STEAP1, triggers internalization of the conjugate complex, mediates intracellular release of monomethyl auristatin E, inhibits cell division, and induces cell death. Vandortuzumab vedotin exhibits antitumor activity in preclinical prostate cancer xenografts. Vandortuzumab vedotin can be used for the research of metastatic castration-resistant prostate cancer .

HY-P992209

Anti-CD318/CDCP1 Antibody (25A11)	Transmembrane Glycoprotein	Cancer
Anti-CD318/CDCP1 Antibody (25A11) is an anti-CDCP1 antibody. Anti-CD318/CDCP1 Antibody (25A11) drives the internalization of antibody-CDCP1 complexes, inhibits cancer cell migration and invasion, and blocks downstream migration/invasion signaling pathways. When conjugated with saponin, Anti-CD318/CDCP1 Antibody (25A11) mediates the killing of prostate cancer cells. When conjugated with saponin, this antibody acts as an immunotoxin to inhibit the growth and metastasis of primary prostate tumors in mouse xenograft models. Anti-CD318/CDCP1 Antibody (25A11) is applicable to prostate cancer-related research .

HY-P992094

Capromab	PSMA	Cancer
Capromab is an anti-human PSMA-targeting monoclonal antibody. Capromab binds specifically to the intracellular domain of PSMA, does not undergo internalization after binding, and targets necrotic cells with disrupted membranes. Capromab can be used for the research of prostate cancer .

HY-P992161

REGN-10597	Interleukin Related PD-1/PD-L1	Inflammation/Immunology Cancer
REGN-10597, composed of an anti-huPD-1-targeting antibody and IL2Ra-IL2 moiety, is a PD-1-dependent IL-2 agonist. REGN-10597 binds PD-1 to deliver masked native IL-2 to PD-1⁺ T cells, engaging trimeric IL-2 receptors to activate downstream signaling. REGN-10597 can be used for the research on melanoma, prostate cancer, colorectal cancer, and ovarian cancer .

HY-P992449

REGN2878 PRLR ADC antibody	ADC Antibody	Cancer
REGN2878 (PRLR ADC antibody) is a monoclonal antibody targeting the prolactin receptor (PRLR) and can block prolactin‑mediated activation of PRLR. REGN2878 exhibits an equilibrium dissociation constant (K_D) of 1.05 nM and an IC₅₀ of 0.344 nM for human PRLR. REGN2878 can be rapidly internalized and degraded in lysosomes by PRLR‑positive tumor cells, showing antigen‑specific binding and targeted enrichment properties. REGN2878 derivatives can be used as an immunoPET agent for antigen‑specific imaging of PRLR‑related tumors, and can also serve as a component of ADCs to exert anti‑tumor activity in breast cancer xenograft models. REGN2878 can be used in the research of breast cancer and prostate cancer. Isotype Comparison HY-P99001 .

HY-P992366

HFB200901	Galectin Tim3	Cancer
HFB200901 is a galectin LGALS9 inhibitor and immunostimulant that can be used in studies related to pancreatic adenocarcinoma, pancreatic intraepithelial neoplasia, KRAS ^G12C-mutant colon cancer, and prostate cancer. HFB200901 disrupts the LGALS9/TIM-3 axis, while blocking the internalization and vacuolization of recombinant LGALS9. HFB200901 reduces the proportion of regulatory T cells (Treg) and enhances dendritic cell activation, thereby inducing polyfunctional and memory CD8 ⁺ T cell responses. HFB200901 inhibits the progression of pancreatic neoplastic lesions and effectively improves the efficacy of PSMA-based vaccination .

HY-P991983

DB-1310 Antibody	ADC Antibody	Cancer
DB-1310 Antibody is a monoclonal antibody inhibitor targeting HER3. DB-1310 Antibody can be used to synthesize the antibody-drug conjugate (ADC) DB-1310. DB-1310 Antibody is applicable to research related to HER3-positive solid tumors, non-small cell lung cancer, breast cancer, colon cancer and prostate cancer .

HY-P991748

Anti-Human/Mouse Amphiregulin Antibody (AR37)	EGFR	Cancer
Anti-Human/Mouse Amphiregulin Antibody (AR37) reacts with human and mouse amphiregulin (AREG) that can block AREG-induced activation of EGFR. Anti-Human/Mouse Amphiregulin Antibody (AR37) can prolong the survival and inhibit the growth of ovarian, breast, and prostate cancer models expressing AREG .

HY-P992347

DS-5573a	CD276/B7-H3	Cancer
DS-5573a is a human monoclonal antibody targeting B7-H3, with a K_d of 1.8 nM for the 4Ig isoform and 11 nM for the 2Ig isoform. DS-5573a induces antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis against B7-H3-expressing cancer cells. DS-5573a exerts dose-dependent anti-tumor activity via effector cells. DS-5573a can be used in the research of cancers including breast adenocarcinoma, non-small cell lung cancer, renal cell adenocarcinoma, gastric cancer and prostate cancer .

HY-P992395

JNJ-64164711 JNJ-711	TNF Receptor NF-κB	Cancer
JNJ-64164711 (JNJ-711) is a bifunctional antibody that simultaneously targets human GITR/TNFRSF18 and FcγRIIIa. JNJ-64164711 binds to the GITR domain to activate the NF-κB signaling pathway, while binding to FcγRIIIa to support antibody-dependent cellular cytotoxicity (ADCC). JNJ-64164711 can specifically eliminate GITR-positive hematological tumor cells, activated T cells and intratumoral regulatory T cells through the ADCC mechanism, thereby significantly enhancing the body's anti-tumor immune response. JNJ-64164711 can be used in research related to non-small cell lung cancer, colorectal cancer, prostate cancer, renal cell carcinoma and hematological tumors .

HY-P992374

huDMB5F3 DMB5F3; chDMB5F3	Mucin	Cancer
huDMB5F3 (DMB5F3; chDMB5F3) is a human monoclonal antibody against human CD227/MUC1, with a K_a value of 5.89 pM for its human target. huDMB5F3 enters MUC1-positive cancer cells via a temperature-dependent internalization process. huDMB5F3 induces cytotoxicity in MUC1-positive cancer cells. huDMB5F3 can be used in the research of various cancers including breast cancer, pancreatic cancer and gastric cancer .

Host:	Mouse (1) Rabbit (2)
Reactivity:	Human (3)
Application:	IHC-P (2) FC (1) ELISA (1)
Isotype:	IgG (2)
Conjugation:	Non-conjugated (3)
Clonality:	Monoclonal (2) Recombinant (1)
Modification:	Unmodified (2)

Cat. No.	Compare	상품명	Application	Reactivity	Image

HY-P81365

	SLC45A3 Antibody (YA1110) PCANAP6; PRST; Slc45a3; Solute carrier family 45 member 3; prostate cancer-associated protein 6; Prostein	IHC-P	Human
	SLC45A3 Antibody (YA1110) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SLC45A3.

HY-P81365A

	SLC45A3 Antibody (YA1110)(PBS only) PCANAP6; PRST; Slc45a3; Solute carrier family 45 member 3; prostate cancer-associated protein 6; Prostein	IHC-P	Human
	SLC45A3 Antibody (YA1110) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SLC45A3.

HY-P85009

	CD82 Antibody (YA4701) 4F9 antibody; Antigen detected by monoclonal and antibody IA4 antibody; C33 antibody; C33 antigen antibody; CD 82 antibody; CD82 antibody; CD82 antigen antibody; CD82 molecule antibody; CD82_HUMAN antibody; GR 15 antibody; GR15 antibody; IA 4 antibody; IA4 antibody; Inducible membrane protein antibody; Inducible membrane protein R2 antibody; KAI 1 antibody; KAI1 antibody; Kangai 1; suppression of tumorigenicity 6; prostate; CD82 antigen; R2 leukocyte antigen; antigen detected by monoclonal and antibody IA4; antibody; Kangai 1 antibody; Kangai1 antibody; Leukocyte surface antigen R2 antibody; Metastasis suppressor Kangai 1 antibody; Metastasis suppressor Kangai-1 antibody; Metastasis suppressor Kangai1 antibody; prostate cancer antimetastasis gene KAI1 antibody; R2 antibody; R2 leukocyte antigen antibody; SAR 2 antibody; SAR2 antibody; ST 6 antibody; ST6 antibody; Suppression of tumorigenicity 6 antibody; Suppression of tumorigenicity 6 prostate antibody; Suppressor of tumorigenicity 6 antibody; Suppressor of tumorigenicity 6 protein antibody; Tetraspanin 27 antibody; Tetraspanin-27 antibody; Tetraspanin27 antibody; Tspan 27 antibody; Tspan-27 antibody; Tspan27 antibody; CD82 nanobody;	ELISA, FC	Human
	CD82 Antibody (YA4701) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to CD82.

Compare Products


Products	해외재고보유 - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / 해외재고보유 - + 장바구니에 담기 견적 받기

Cat. No.	상품명		Classification

HY-114402

ARD-69		PROTAC Synthesis
ARD-69 is a PROTAC degrader based on the E3 ubiquitin ligase VHL and targeting the androgen receptor, which can induce androgen receptor (AR) protein degradation in AR-positive prostate cancer cells. ARD-69 inhibits AR-regulated gene expression, binds to the AR ligand binding domain at one end and binds to VHL at the other end, prompting AR to be recruited to the E3 ubiquitin ligase complex, triggering proteasome degradation, thereby inhibiting AR signaling pathways and downstream gene expression (such as PSA, TMPRSS2). ARD-69 can be used to study of castration-resistant prostate cancer (mCRPC) . ARD-69 is composed of a target protein ligand (pink part) AR antagonist 14 (HY-172624), a PROTAC linker (black part) tert-Butyl 4-ethynyl-[1,4'-bipiperidine]-1'-carboxylate (HY-W442074), and a VHL-type E3 ubiquitinase ligand (blue part) VH 101, acid (HY-47070); among them, the VHL ligand and the linker can form a conjugate VH 101-amide-piperidine-Pip-alkyne (HY-172625).

HY-133020

ARD-266		PROTAC Synthesis
ARD-266 is a highly potent and von Hippel-Lindau E3 ligase-based Androgen Receptor (AR) PROTAC degrader. ARD-266 effectively induces degradation of AR protein in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines with DC₅₀ values of 0.2-1 nM . ARD-266 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-147526

RM-581		Alkynes
RM-581, aminosteroid, is an orally active anticancer agent. RM-581 shows anticancer potency against pancreatic, breast, prostate, and ovarian cancers. RM-581 induces endoplasmic reticulum stress and apoptosis via disturbance of cancer cell cholesterol homeostasis. RM-581 can be used for the research of cancer, such as prostate cancer and breast cancer .

HY-145259

HDAC6-IN-3		Alkynes
HDAC6-IN-3 (Compound 14), an antiprostate cancer agent, is a potent, orally active HDAC6 inhibitor with IC₅₀s ranging from 0.02-1.54 μM for HDAC1/2/3/6/8/10. HDAC6-IN-3 is also an effective MAO-A (IC₅₀=0.79 μM) and LSD1 inhibitor . HDAC6-IN-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-114759

MS-PPOH 1 Publications Verification		Alkynes
MS-PPOH is a potent and selective cytochrome P450 (CYP) epoxygenase inhibitor . MS-PPOH inhibits CYP2C8 and CYP2C9 with IC₅₀s of 15 and 11 μM, respectively . MS-PPOH is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-149408

MAOA-IN-1		Alkynes
MAOA-IN-1 (compound 15) is an orally active MAOA inhibitor with cytotoxicity against prostate cancer cells. MAOA-IN-1 has Caco-2 permeability and lower CNS permeability. MAOA-IN-1 can be further used in the research of anti-cancer and anti-inflammatory indications .

HY-16247

Apoptone HE3235		Alkynes
Apoptone (HE3235) is an orally active 3β-androstanediol analog. Apoptone reduces the expression of androgen receptor (Androgen receptor) and decreases intratumoral androgen levels. Apoptone exhibits anticancer activity against castration-resistant prostate cancer .

HY-169098

HSP90/LSD1-IN-1		Alkynes
HSP90/LSD1-IN-1 (compound 6) is a HSP90/LSD1 dual inhibitor. HSP90/LSD1-IN-1 inhibits the proliferation of prostate cancer cell lines PC-3 and DU145, with GI₅₀ values of 0.24 and 0.30 μM, respectively .

Cat. No.	상품명		Classification

HY-N0171

Beta-Sitosterol (purity>80%) Maximum Cited Publications 22 Publications Verification		Cholesterol
Beta-Sitosterol (purity≥80%) is orally active. Beta-Sitosterol exhibits multiple activities, including anti-inflammatory, anticancer, antioxidant, antimicrobial, antidiabetic, antioxidant enzyme, and analgesic. Beta-Sitosterol inhibits inflammation and impaired adipogenesis in bovine mammary epithelial cells by reducing levels of ROS, TNF-α, IL-1β, and NF-κB p65 and restoring the activity of the HIF-1α/mTOR signaling pathway. Beta-Sitosterol induces apoptosis in cancer cells through ROS-mediated mitochondrial dysregulation and p53 activation. Beta-Sitosterol exerts its anticancer effects in cancer cells by activating caspase-3, caspase-8, and caspase-9, mediating PARP inactivation, MMP loss, altered Bcl-2-Bax ratio, and cytochrome c release. Beta-Sitosterol modulates macrophage polarization and reduces rheumatoid inflammation in mice. Beta-Sitosterol inhibits tumor growth in multiple mouse cancer models. Beta-Sitosterol can be used in the research of arthritis, lung cancer, breast cancer and other cancers, diabetes, etc .

HY-113217

Cholesteryl oleate 1 Publications Verification		Cholesterol
Cholesteryl oleate is an ester compound formed from Cholesterol (HY-N0322) and Oleic acid (HY-N1446), which is involved in lipid transport, storage and cell membrane formation in living organisms. Cholesteryl oleate may serve as a potential biomarker for prostate cancer. Cholesteryl oleate can also prepare cationic solid lipid nanoparticles (SLNs) for efficient gene silencing .

HY-113289

Brassicasterol 1 Publications Verification		Cholesterol
Brassicasterol is a metabolite of Ergosterol and has cardiovascular protective effects. Brassicasterol exerts anticancer effects in prostate cancer through dual targeting of AKT and androgen receptor signaling pathways. Brassicasterol inhibits HSV-1 (IC₅₀=1.2 μM) and Mycobacterium tuberculosis. Brassicasterol also inhibits sterol δ 24-reductase, slowing the progression of atherosclerosis. Brassicasterol is also a cerebrospinal fluid biomarker for Alzheimer's disease .

HY-147081

AS 1411 2 Publications Verification AGRO-100		Aptamers
AS 1411 (AGRO-100) is an oligonucleotide aptamer targeting nucleoproteins. AS 1411 inhibits tumor cell proliferation by affecting the activity of nucleoprotein-containing complexes and can be used as a carrier to precisely deliver nanoparticles, oligonucleotides and small molecules to cancer cells. AS 1411 reduces PRMT5 expression to inhibit tumor growth in DU145 prostate cancer cells. AS 1411 works by blocking the binding of nucleoproteins to bcl-2 mRNA in MCF-7 breast cancer cells. AS 1411-coupled Jin nanospheres can inhibit breast cancer cell proliferation in vitro and in mouse models, has the ability to cross the blood-brain barrier with low tissue toxicity .

HY-145722

Apatorsen sodium 1 Publications Verification OGX-427 sodium		Antisense Oligonucleotides
Apatorsen (OGX-427) sodium is a 2'-methoxyethyl-modified antisense oligonucleotide and also a Hsp27 inhibitor. Apatorsen sodium reduces Hsp27 mRNA and protein levels, impairs stress-induced cytoprotective functions, induces cell apoptosis, inhibits tumor growth and prevents metastasis. Apatorsen sodium is applicable to research related to non-small cell lung cancer, castration-resistant prostate cancer, breast cancer, ovarian cancer and bladder cancer .

HY-Y1887

Cottonseed oil		Solvents
Cottonseed oil is an edible oil extracted from the seeds of cotton (Gossypium hirsutum). Its fatty acid composition includes 26-35% saturated fatty acids, 42-52% polyunsaturated fatty acids, and 18-24% monounsaturated fatty acids. Cottonseed oil is regarded as an Insecticide, as it is used to protect the trunks of apple trees from damage by the apple clearwing moth. Cottonseed oil possesses anti-inflammatory and cardioprotective properties. It also has extensive applications in many fields such as biofuels, animal husbandry, cosmetics, agriculture, and chemical industry .

HY-173189A

2-5A pentasodium solution (100 mM) 2′,5′-ApApA pentasodium; 2′,5′-trioligoadenylate pentasodium; 5'-O-Triphosphoryladenylyl-(2'→5')-adenylyl-(2'→5')-adenosine pentasodium		Nucleotide Analogs Adenine Nucleotide
2-5A (2′,5′-ApApA) pentasodium solution 100 mM is a high-affinity (K_a=0.04 nM) RNase L binder. 2-5A pentasodium solution 100 mM activates the nuclease activity of latent RNase L to cleave single-stranded RNA by inducing conformational changes and dimerization of latent RNase L, thereby mediating critical antiviral responses and enhancing interferon effects. 2-5A pentasodium solution 100 mM not only effectively inhibits Rauscher murine leukemia virus replication, reduces viremia and splenomegaly, but also enhances antileukemic efficacy when combined with amphotericin B and exhibits favorable high-dose tolerance. 2-5A pentasodium solution 100 mM is an important tool molecule for investigating the pathological mechanisms of viral infection, hereditary prostate cancer and leukemia .

HY-W587488

Adenosine 3′-monophosphate 3′-AMP		Nucleotide Analogs Adenine Nucleotide
Adenosine 3’-monophosphate (3’-AMP) is a nucleotide. Adenosine 3’-monophosphate is a cyclic AMP production agonist. Adenosine 3’-monophosphate increases cyclic AMP levels concentration-dependently in NG108-15 cells. Adenosine 3’-monophosphate can be used in the determination of acid phosphatase activity of human serum, which is estabilished as a laboratory procedure in the diagnosis of prostate cancer, metastatic mammary cancer and Gaucher’s disease. Adenosine 3’-monophosphate inhibits human aortic and coronary vascular smooth muscle cell proliferation via A_2B receptors .

HY-145722A

Apatorsen 1 Publications Verification OGX-427		Antisense Oligonucleotides
Apatorsen is a 2'-methoxyethyl-modified antisense oligonucleotide and also a Hsp27 inhibitor. Apatorsen reduces Hsp27 mRNA and protein levels, impairs stress-induced cytoprotective functions, induces cell apoptosis, inhibits tumor growth and prevents metastasis. Apatorsen is applicable to research related to non-small cell lung cancer, castration-resistant prostate cancer, breast cancer, ovarian cancer and bladder cancer .

HY-147081A

AS 1411 sodium 2 Publications Verification AGRO-100 sodium		Aptamers
AS 1411 (AGRO-100) sodium is an oligonucleotide aptamer targeting nucleoproteins. AS 1411 sodium inhibits tumor cell proliferation by affecting the activity of nucleoprotein-containing complexes and can be used as a carrier to precisely deliver nanoparticles, oligonucleotides and small molecules to cancer cells. AS 1411 sodium reduces PRMT5 expression to inhibit tumor growth in DU145 prostate cancer cells. S 1411 sodium works by blocking the binding of nucleoproteins to bcl-2 mRNA in MCF-7 breast cancer cells. S 1411 sodium-coupled Jin nanospheres can inhibit breast cancer cell proliferation in vitro and in mouse models, has the ability to cross the blood-brain barrier with low tissue toxicity

HY-143209B

DSPE-PEG3400		Pegylated Lipids
DSPE-PEG3400 is a phospholipid-PEG polymer conjugate that can be used in drug delivery applications. DSPE-PEG3400 serves as a material for preparing nanocarriers, which is used to prolong blood circulation time, enhance stability and improve encapsulation efficiency .

HY-155887

DSPE-PEG-Amine, MW 3400 ammonium DSPE-PEG-NH2, MW 3400 ammonium		Pegylated Lipids
DSPE-PEG-Amine (DSPE-PEG-NH2), MW 3400 ammonium is an amino-functionalized PEGylated phospholipid. It serves not only as a key component for preparing σ receptor-targeted liposomes (such as anisamide-modified lipids) but also as a starting material for synthesizing click chemistry- and tumor-targeted lipids including DSPE-PEG-DBCO (HY-155788) and DSPE-PEG2000-TCO (HY-170704). DSPE-PEG-Amine, MW 3400 ammonium effectively modulates the ζ potential of nanoparticles, enables complexation with nucleic acids or proteins to protect DNA from nuclease degradation, and supports ligand conjugation on the nanoparticle surface. It is used in studies related to DU-145 tumors, breast cancer, and other relevant research .

HY-143230

Custirsen OGX-011		Antisense Oligonucleotides
Custirsen (OGX-011) is an antisense oligonucleotide that targets clusterin mRNA. Custirsen induces apoptosis by activating Bax, triggering mitochondrial translocation and cytochrome c release. Custirsen acts as a chemosensitizer, radiosensitizer and hormone sensitizer. Custirsen can be used in research related to prostate cancer, non-small cell lung cancer and metastatic breast cancer .

HY-160046

AS2 sodium		Aptamers
AS2 sodium is an ssDNA aptamer (Kd: 0.7 nM) for prostate-specific antigen (PSA). AS2 sodium does not bind non-specifically to the anti-target and has the potential to be used in diagnostic systems for prostate cancer detection .

온라인 문의

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

prostate cancer

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

GMP Molecules

Natural
Products